丹娜生物
(920009)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | - | 325,580,866.32 | 310,583,665.98 | 389,428,484.62 |
| 交易性金融资产 | - | 110,282,648.21 | 97,113,293.76 | - |
| 应收票据及应收账款 | - | 7,923,271.87 | 6,649,946.46 | 4,815,729.35 |
| 应收账款 | - | 7,923,271.87 | 6,649,946.46 | 4,815,729.35 |
| 预付款项 | - | 4,526,965.99 | 4,927,846.89 | 4,457,145.6 |
| 其他应收款合计 | - | 160,011.4 | 186,042.74 | 191,158.64 |
| 存货 | - | 23,203,456.96 | 21,816,095.69 | 21,781,723.01 |
| 其他流动资产 | - | 13,002,130.21 | 10,824,221.12 | 10,306,385.4 |
| 流动资产平衡项目 | - | 0 | 0 | 0 |
| 流动资产合计 | - | 484,679,350.96 | 452,101,112.64 | 430,980,626.62 |
| 非流动资产: | | | | |
| 固定资产 | - | 54,385,211.99 | 53,788,455.15 | 54,719,546.57 |
| 在建工程 | - | 3,853,361.39 | 4,789,758.78 | 4,641,584.44 |
| 使用权资产 | - | 2,850,245.11 | 3,241,205.79 | 3,570,374.47 |
| 无形资产 | - | 12,274,166.5 | 12,341,116.51 | 12,422,244.52 |
| 长期待摊费用 | - | 6,947,568.45 | 7,815,126.28 | 8,708,669.02 |
| 递延所得税资产 | - | 4,494,492.77 | 4,332,148.66 | 3,921,832.68 |
| 其他非流动资产 | - | 1,076,420 | 580,089.5 | 497,089.5 |
| 非流动资产平衡项目 | - | 0 | 0 | 0 |
| 非流动资产合计 | - | 85,881,466.21 | 86,887,900.67 | 88,481,341.2 |
| 资产平衡项目 | - | 0 | 0 | 0 |
| 资产总计 | 592,796,100 | 570,560,817.17 | 538,989,013.31 | 519,461,967.82 |
| 流动负债: | | | | |
| 应付票据及应付账款 | - | 5,247,840.15 | 5,043,273.38 | 2,979,047.07 |
| 应付账款 | - | 5,247,840.15 | 5,043,273.38 | 2,979,047.07 |
| 合同负债 | - | 21,818,822.42 | 18,462,601.97 | 14,451,902.21 |
| 应付职工薪酬 | - | 10,792,688.41 | 6,446,676.66 | 15,962,337.49 |
| 应交税费 | - | 3,042,509.5 | 3,441,072.46 | 1,128,454.16 |
| 其他应付款合计 | - | 883,590.47 | 898,298.03 | 6,791,756.33 |
| 一年内到期的非流动负债 | - | 1,417,581.42 | 1,468,877.88 | 1,460,349.88 |
| 其他流动负债 | - | 726,078.54 | 350,748.8 | 142,285.57 |
| 流动负债平衡项目 | - | 0 | 0 | 0 |
| 流动负债合计 | - | 43,929,110.91 | 36,111,549.18 | 42,916,132.71 |
| 非流动负债: | | | | |
| 租赁负债 | - | 1,883,802.97 | 2,209,692.7 | 2,560,520.85 |
| 预计负债 | - | 3,320,388.26 | 3,320,388.26 | 3,320,388.26 |
| 递延收益 | - | 4,116,920.55 | 3,846,632.16 | 3,996,343.77 |
| 递延所得税负债 | - | 2,827,585.23 | 2,763,512.59 | 3,021,938.78 |
| 非流动负债平衡项目 | - | 0 | 0 | 0 |
| 非流动负债合计 | - | 12,148,697.01 | 12,140,225.71 | 12,899,191.66 |
| 负债平衡项目 | - | 0 | 0 | 0 |
| 负债合计 | 57,034,800 | 56,077,807.92 | 48,251,774.89 | 55,815,324.37 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | - | 47,390,000 | 47,390,000 | 47,390,000 |
| 资本公积 | - | 117,494,603.96 | 117,058,879.22 | 116,623,154.48 |
| 盈余公积 | - | 23,695,000 | 23,695,000 | 23,695,000 |
| 未分配利润 | - | 325,903,405.29 | 302,593,359.2 | 275,938,488.97 |
| 归属于母公司股东权益平衡项目 | - | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 535,761,300 | 514,483,009.25 | 490,737,238.42 | 463,646,643.45 |
| 股东权益平衡项目 | - | 0 | 0 | 0 |
| 股东权益合计 | - | 514,483,009.25 | 490,737,238.42 | 463,646,643.45 |
| 负债和股东权益合计 | - | 570,560,817.17 | 538,989,013.31 | 519,461,967.82 |
| 公告日期 | 2025-10-20 | 2025-07-07 | 2025-04-29 | 2025-01-15 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |